Información de la revista
Vol. 49. Núm. 2.
Páginas 35-37 (febrero 2002)
Vol. 49. Núm. 2.
Páginas 35-37 (febrero 2002)
Acceso a texto completo
Hipertiroidismo en la enfermedad de Graves-Basedow. ¿Podemos predecir la remisión?
Visitas
12441
Servicio de Endocrinología. Departamento de Medicina. Hospital Clínico Universitario. Salamanca
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.P. Weetman.
Graves’ disease.
N Engl J Med, 343 (2000), pp. 1236-1248
[2.]
J.C. GalogréJ, R.V. García-Mayor, E. Fluiters, L. Fernández-Calvet, A. Rego, C. Páramo, et al.
Incidence of different forms of thyroid dysfunction and its degrees in an iodine sufficient area.
Thyroidol Clin Exp, 6 (1994), pp. 49-54
[3.]
T.H. Brix, K.O. Kyvik, K. Christensen, L. Hegedüs.
Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts.
J Clin Endocrinol Metab, 86 (2001), pp. 930-934
[4.]
J.J. Corrales, A. López, J. Ciudad, M.T. Mories, J.M. Miralles, A. Orfao.
Methimazole therapy in Graves’ disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
J Endocrinol, 155 (1997), pp. 491-500
[5.]
J.J. Corrales, A. Orfao, A. López, M.T. Mories, J.M. Miralles, J. Ciudad.
Análisis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves’ disease: relationship with disease activity.
Cytometry, 30 (1997), pp. 118-123
[6.]
D. Reinwein, G. Benker, J.H. Lazarus, W.D. Alexander.
and the European Multicenter Study Group on antithyroid drug treatment. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy.
J Clin Endocrinol Metab, 76 (1993), pp. 1516-1521
[7.]
A. Lucas, I. Salinas, F. Rius, E. Pizarro, M.L. Granada, M. Foz, et al.
Medical therapy of Graves’ disease: does thyroxine prevent recurrence of hyperthyroidism?.
J Clin Endocrinol Metab, 82 (1997), pp. 2410-2413
[8.]
P. Vitti, T. Rago, L. Chiovato, S. Pallini, F. Santini, E. Fiore, et al.
Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment.
Thyroid, 7 (1997), pp. 369-375
[9.]
O. Sabri, M. Zimny, G. Schultz, M. Schreckenberger, P. Reinartz, K. Willmes, et al.
Success rate of radioiodine therapy in Graves’ disease: the influence of thyrostatic medication.
J Clin Endocrinol Metab, 84 (1999), pp. 1229-1233
[10.]
D. Glinoer, D. Hesch, R. Lagasse, P. Laurberg.
The management of hyperthyroidism due to Graves’ disease in Europe in 1986 Results of an international survey.
Acta Endocrinol, 115 (1987), pp. 1-23
[11.]
H. Schleusener, J. Schwander, C. Fischer, R. Holle, G. Holl, K. Badenhoop, et al.
Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves’ disease.
Acta Endocrinol, 120 (1989), pp. 689-701
[12.]
A. Allahabadia, J. Daykin, R.L. Holder, M.C. Sheppard, S.C.L. Gough, J.A. Franklyn.
Age and gender predict the outcome of treatment for Graves’ hyperthyroidism.
J Clin Endocrinol Metab, 85 (2000), pp. 1038-1042
[13.]
N.S. Glaser, D.M. Styne.
Predictors of early remission of hyperthyroidism in children.
J Clin Endocrinol Metab, 82 (1997), pp. 1719-1726
[14.]
A.P. Weetman, S. Ratanachaiyavong, G.W. Middleton, W. Love, R. John, G.M. Owen, et al.
Prediction of outcome in Graves’ disease after carbimazole treatment.
Quart J Med, 228 (1986), pp. 409-419
[15.]
B. Winsa, P.A. Dahlberg, R. Jansson, H. Agren, F.A. Karlsson.
Factors influencing the outcome of thyrostatic drug therapy in Graves’ disease.
Acta Endocrinol, 122 (1990), pp. 722-728
[16.]
W. Raber, E. Kmen, W. Waldhäusl, H. Vierhapper.
Medical therapy of Graves’ disease: effect on remission rates of methimazole alone and in combination with triiodothyronine.
Eur J Endocrinol, 142 (2000), pp. 117-124
[17.]
V. Michelangelli, C. Poon, J. Taft, H. Newnham, D. Topliss, P. Colman.
The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves’ disease with antithyroid drugs.
Thyroid, 8 (1998), pp. 119-124
[18.]
N. Takasu, K. Yamashiro, I. Komiya, Y. Ochi, Y. Sato, A. Nagata.
Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Thyroid, 10 (2000), pp. 891-896
[19.]
S. Costagliola, N.G. Morgenthaler, R. Hoermann, K. Badenhoop, J. Struck, D. Freitag, et al.
Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease.
J Clin Endocrinol Metab, 84 (1999), pp. 90-97
[20.]
D. Maugendre, C. Massart.
Clinical value of a new TSH binding inhibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves’ disease. Comparison with thyroid stimulating antibody bioassay.
Clin Endocrinol, 54 (2001), pp. 89-96
[21.]
C. Massart, J. Orgiazzi, D. Maugendre.
Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves’ disease treated with antithyroid drugs.
Clin Chim Acta, 304 (2001), pp. 39-47
[22.]
M. Zingrillo, L. D’Aloiso, M.R. Ghiggi, A. Di Cerbo, I. Chiodini, M. Torlontano, et al.
Thyroid hypoechogenicity after methimazole withdrawal in Graves’ disease: a useful index for predicting recurrence?.
Clin Endocrinol, 45 (1996), pp. 201-206
[23.]
K. Varsamidis, E. Varsamidou, G. Mavropoulos.
Doppler ultrasonography in predicting relapse of hyperthyroidism in Graves’ disease.
Acta Radiol, 41 (2000), pp. 45-48
[24.]
J.J. Corrales, A. López, J. Ciudad, A. Orfao.
The distribution of the major peripheral blood T, B and NK cell subsets does not predict the clinical outcome of Graves’ disease patients after methimazole therapy.
J Biol Regul Homeost Agents, 14 (2000), pp. 193-199
[25.]
K. Badenhoop, H. Donner, J. Braun, T. Siegmund, H. Rau, K.H. Usadel.
Genetic markers in diagnosis and prediction of relapse in Graves’ disease.
Exp Clin Endocrinol Diabetes, 104 (1996), pp. 98-100
[26.]
K. Hashizume, K. Ichikawa, A. Sakurai, S. Suzuki, T. Takeda, M. Kobayashi, et al.
Administration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
N Engl J Med, 324 (1991), pp. 947-953
[27.]
R.S. Rittmaster, E.C. Abbott, R. Douglas, M.L. Givner, L. Lehmann, S. Reddy, et al.
Effect of methimazole, with or without L-thyroxine, on remission rates in Graves’ disease.
J Clin Endocrinol Metab, 83 (1998), pp. 814-818
[28.]
G. Benker, D. Reinwein, G. Kahaly, L. Tegler, W.D. Alexander, J. Fassbinder, et al.
Is there a methimazole dose effect on remission rate in Graves’ disease? Results from a long-term prospective study.
Clin Endocrinol, 49 (1998), pp. 451-457
[29.]
H. Allannic, R. Fauchet, J. Orgiazzi, A.M. Madec, B. Genetet, Y. Lorcy, et al.
Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration.
J Clin Endocrinol Metab, 70 (1990), pp. 675-679
[30.]
D. Maugendre, A. Gatel, L. Campion, C. Massart, I. Guilhem, Y. Lorcy, et al.
Antithyroid drugs and Graves’ disease-Prospective randomized assessment of long-term treatment.
Clin Endocrinol, 50 (1999), pp. 127-132
Copyright © 2002. Sociedad Española de Endocrinología y Nutrición